Shares of Alexion Pharmaceuticals, Inc. (ALXN) traded 1.64 points or 1.25% higher at $132.32.The total intraday money flow for the shares came in at a disappointing $(-6.15) million. The total upticks amounted to $73.69 million and the total downticks were approximately $79.84 million, with the up/down ratio of 0.92. On a different note, the shares have seen 2.39% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $15.19 million in upticks and an outflow of $15.27 million in downticks. The up/down ratio for the block was found to be 1. The net money flow for the block transaction was $(-0.07) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Alexion Pharmaceuticals, Inc. rose by 2.21% in the last five trading days and 8.15% for the last 4 weeks. Alexion Pharmaceuticals, Inc. is up 1.39% in the last 3-month period. Year-to-Date the stock performance stands at 8.15%. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rose 1.25% or 1.64 points on Wednesday and made its way into the gainers of the day. After trading began at $128.5 the stock was seen hitting $132.84 as a peak level and $128.5 as the lowest level. The stock ended up at $132.32. The daily volume was measured at 2,327,563 shares. The 52-week high of the share price is $162 and the 52-week low is $109.12. The company has a market cap of $29,631 million.
Company has reported several Insider transactions to the SEC, on Jan 13, 2017, Leonard Bell (director) sold 100 shares at 144.99 per share price.On Jan 9, 2017, Alvin S Parven (director) sold 22,659 shares at 137.86 per share price.On Dec 13, 2016, Carsten Thiel (EVP, Chief Commercial Officer) sold 2,308 shares at 130.00 per share price.
Alexion Pharmaceuticals Last issued its quarterly earnings results on Oct 27, 2016. The company reported $1.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $1.17. The company had revenue of $799.10 million for the quarter, compared to analysts expectations of $786.61 million. The companys revenue was up 19.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.16 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Alexion Pharmaceuticals was Reiterated by RBC Capital Mkts on Dec 22, 2016 to Outperform, Lowers Price Target to $ 187 from a previous price target of $188 .Alexion Pharmaceuticals was Initiated by Oppenheimer to Perform on Dec 15, 2016. Alexion Pharmaceuticals was Downgraded by Morgan Stanley to Equal-Weight on Dec 13, 2016.
Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The companys lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.